A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)

Trial Profile

A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Alteplase (Primary) ; Aspirin
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms PRISMS
  • Sponsors Genentech
  • Most Recent Events

    • 09 May 2017 Status changed from active, no longer recruiting to discontinued.
    • 20 Feb 2017 Status changed from discontinued to active, no longer recruiting.
    • 17 Feb 2017 Planned End Date changed from 1 May 2018 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top